Hope amid challenging times for antibiotic developers
In recent years, much of the news coverage around antibiotic development has been, for lack of a better word, gloomy.
There’s good reason for that. As reports from the World Health Organization and other concerned groups have concluded, the pipeline for new antibiotics is not nearly robust enough to meet the growing challenge of antimicrobial resistance (AMR). Many large pharmaceutical companies have abandoned development because there’s simply not enough money to be made on new antibiotics, especially with the increasing focus on antibiotic stewardship.
That leaves the bulk of antibiotic research and development (R&D) to small biotechnology companies which, despite having promising antibacterial and antifungal products that are urgently needed, face funding shortfalls and the prospect of bankruptcy.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.